02269.HK
WuXi Biologics (Cayman) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 50.35
+0.50%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 50.35
From 52W high−3.54%
Volume37.15M
Market capHKD 202.78B
P/E (TTM)35.6x
P/S (TTM)7.3x
Div yield—
Key dataSep 18, 2026
Open
HKD 50.35
From 52W high
−3.54%
Volume
37.15M
Market cap
HKD 202.78B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
19.2x
P/E (TTM)
35.6x
RSI (14)
60.1
MomentumView details →
1D Return
+0.50%
YTD Return
+60.15%
Similar companies
Latest newsMore news →
WuXi Biologics signed an agreement to land a commercial high-end manufacturing platform project in Wuxi, including new biologic drug production lines and supporting process development laboratories.4d agoHong Kong stocks closed higher on September 14, 2026, with the Hang Seng Index up 111 points or 0.5% at 24,917, while the Hang Seng Tech Index slipped 2 points or 0.1% to 4,317 and the China Enterprises Index rose 38 points or 0.5% to 8,284 on turnover of HK$192.625 billion.6d agoHong Kong stocks closed the morning session higher on September 14, 2026, with the Hang Seng Index up 87 points at 24,893 and the Hang Seng Tech Index up 7 points at 4,327.7d ago